BTSG heads into its July 30 earnings with one of the most consistently bullish analyst tapes in healthcare services — and a stock that has already moved 22% higher in a month.
The analyst conviction story is unusually clean. UBS raised its target to $85 from $63 on July 8, keeping a Buy rating, just days after BofA lifted to $77 from $66. Before that, BTIG went to $90, TD Cowen to $81, and Goldman Sachs initiated at $71 in early June. Morgan Stanley, already Overweight, has raised its target twice since May. Every recent move has been an upgrade or raise — not a single cut in the sequence. The consensus mean target of $68.38 now sits fractionally below the current price of $70.17, meaning the stock has already run through the average, but the cluster of targets in the $77-$90 range keeps a meaningful portion of the Street above where the stock trades today. Bulls point to BrightSpring's pharmacy solutions franchise and its Medicare/Medicaid exposure as durable growth drivers. Bears counter with rising cost trends, membership pressure, and a conservative guidance posture that jars with the Q1 beat — a mix that suggests management is deliberately anchoring expectations ahead of the July 30 print.
The lending market is not what drives this story. Borrow availability is exceptionally loose — roughly 1,179% of current short interest, meaning there are about twelve shares available to borrow for every one already lent out, well above the 52-week floor of 141%. Cost to borrow is 0.52%, effectively negligible. Short interest of 5.7% of free float has ticked down about 6.5% on the week after a brief spike in late June that pushed shares short to around 11 million. The ORTEX short score of 43.5 is mid-range and drifting lower — there is no meaningful short-side pressure here. Options positioning similarly reads as relaxed: the put/call ratio of 0.77 is below its 20-day average of 0.82, nearly a full standard deviation light on downside hedging. Together, the positioning data reflects a market leaning with the stock rather than against it.
The ownership picture adds a notable wrinkle. KKR, still the largest disclosed holder with 12.9% of shares, sold approximately 14.7 million shares on June 5 at $58.75 — a transaction worth around $857 million. The CEO sold 130,000 shares the same day, and the CFO sold 35,000. That scale of insider distribution would typically weigh on sentiment, yet the stock has continued higher. The pattern suggests the selling was absorbed cleanly, likely into the wave of institutional interest that built through June. BlackRock added 2.4 million shares through end of June, T. Rowe Price added 1.5 million through May, and State Street added roughly 860,000. The distribution appears to have transferred stock from the sponsor into institutional hands without dislodging the bid.
The earnings history, thin as it is, shows a pattern worth watching. The May 1 Q1 print delivered an 11.6% one-day gain and a 14.3% five-day move — a sizable positive surprise that reset expectations sharply upward and appears to be the engine behind the current run. The most recent event on May 21 was flat on the day. With the stock now at $70 and the mean target just below that level, the July 30 Q2 result is less about whether BrightSpring is growing and more about whether management lifts guidance enough to validate targets in the $77-$90 range now being published.
See the live data behind this article on ORTEX.
Open BTSG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
